Drug Trial Radar · NCT07948447
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO 1306 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- NeolaiaBioIndustry
- Sponsor type
- Industry
- Collaborators
- NeolaiaBio Aus Pty Ltd
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
NEO-1306 is being developed for the treatment of moderately to severely active inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). This will be the first study - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO-1306 in Healthy Participants.
Conditions
- IBD (Inflammatory Bowel Disease)
- Healthy Adult Participants
Interventions
NEO-1306Drug
NEO-1306, single Dose #1
NEO-1306Drug
NEO-1306, single Dose #2
NEO-1306Drug
NEO-1306, single Dose #3
NEO-1306Drug
NEO-1306, single Dose #4
NEO-1306Drug
NEO-1306, single Dose #5
NEO-1306Drug
NEO-1306, single Dose #6
NEO-1306Drug
NEO-1306, Multiple Dose #1, single dose once per day for 14 days
NEO-1306Drug
NEO-1306, Multiple Dose #2, single dose once per day for 14 days
NEO-1306Drug
NEO-1306, Multiple Dose #3, single dose once per day for 14 days
NEO-1306Drug
NEO-1306, Multiple Dose #4, single dose once per day for 14 days
NEO-1306 PlaceboDrug
SAD Placebo
NEO-1306 PlaceboDrug
MAD Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v6.0Time frame: 7 days for SAD and 25 days for MAD
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.